retatrutide fat loss clinical trial New Phase 3 data just dropped 👀 Eli Lilly's reported average weight approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Retatrutide FDA Approval Status 2026:

instead of being a single GLP-1 receptor agonist like semaglutide, tirzepatide is a GLP-1/glucose insulinotropic peptide (GIP) dual agonist, which explains the greater weight loss it delivers

A supramolecular deferoxamine-crisaborole nanoparticle targets ferroptosis, inflammation, and oxidative stress in the treatment of retinal ischemia/reperfusion injury

GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite through central nervous system effects

The honest answer sits somewhere between the miracle claims on Instagram reels and the flat "it's all a myth" you'll hear from skeptics

Gmelin in 1827